Physician profile
Hunter Marteney
NPI 1346902293
$2,418.85
in general payments reported to CMS, 2019-2025
21 companies · $1,698 in 2025
The $1,698 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $46.81 · 2024: $674 · 2025: $1,698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,254 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,253.91 |
| Education | $164.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $575.85 | 2023-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $306.47 | 2023-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $230.38 | 2025 | Nemluvio |
| Ucb, INC. | $190.67 | 2024-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $139.51 | 2024-2025 | Sotyktu |
| Abbvie INC. | $128.02 | 2024 | |
| Genzyme Corporation | $127.11 | 2024-2025 | |
| Incyte Corporation | $126.03 | 2025 | Opzelura |
| Organon LLC | $121.18 | 2025 | Vtama |
| Pfizer INC. | $76.30 | 2024-2025 | |
| Amgen INC. | $72.80 | 2024-2025 | Otezla, Otezla |
| Smith+Nephew, INC. | $53.60 | 2025 | Collagenase Santyl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.09 | 2024 | Spevigo |
| Arcutis Biotherapeutics, INC. | $45.51 | 2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $35.92 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $31.20 | 2024-2025 | |
| Blueprint Medicines Corporation | $26.94 | 2024 | Ayvakit |
| Botanix Sb INC | $26.14 | 2025 | Sofdra |
| Lnhc, INC | $22.83 | 2025 | Zelsuvmi |
| Verrica Pharmaceuticals INC. | $17.56 | 2025 | Ycanth |
| Lilly USA, LLC | $13.74 | 2025 | Taltz, Ebglyss |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hunter Marteney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.